Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers

Immunotherapy, especially the immune checkpoint inhibitors (ICIs) such as the pembrolizumab and nivolumab have contributed to significant improvements in treatment outcomes and survival of head and neck cancer (HNC) patients. Still, only a subset of patients benefits from ICIs and hence the race is...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Annie Wai Yeeng, Yee, Pei San, Cheong, Sok Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968950/
https://www.ncbi.nlm.nih.gov/pubmed/35372020
http://dx.doi.org/10.3389/fonc.2022.837835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968950/
https://www.ncbi.nlm.nih.gov/pubmed/35372020
http://dx.doi.org/10.3389/fonc.2022.837835

Ejemplares similares